Gap19 and the Future of Selective Connexin 43 Hemichannel...
2025-10-21
Gap19, a selective connexin 43 (Cx43) hemichannel inhibitor peptide, is revolutionizing the landscape of neuroinflammation and neuroprotection research. This thought-leadership article synthesizes mechanistic insights with pragmatic guidance for translational scientists, highlighting Gap19’s role in modulating neuroglial interactions, inhibiting ATP release, and attenuating macrophage polarization through the Cx43/NF-κB pathway. By contextualizing recent experimental evidence and situating Gap19 within the competitive field, we chart a visionary path for its application in stroke, ischemia/reperfusion injury, and beyond.